Fig. 6

Anti-miR-199a-5p-IPF-MSC transplantation ameliorated the symptoms of pulmonary fibrosis. a Schematic chart showing the introduction of bleomycin-induced pulmonary fibrosis and transplantation of control-MSCs, IPF-MSCs, or anti-miR-199a-5p-IPF-MSCs. b HE staining of the lung tissue from control mice, bleomycin-treated mice, bleomycin-treated mice that received control-MSCs, IPF-MSCs, or anti-miR-199a-5p-IPF-MSCs. Scale bar = 100 μm. c Representative images of Masson’s trichrome staining of the lung tissue from control mice, bleomycin-treated mice, bleomycin-treated mice that received control-MSCs, IPF-MSCs, or anti-miR-199a-5p-IPF-MSCs. Scale bar = 100 μm. d Quantitative analysis of fibrosis of the lung tissue from control mice, bleomycin-treated mice, and bleomycin-treated mice that received control-MSCs, IPF-MSCs, or anti-miR-199a-5p-IPF-MSCs. e Representative images of HNA staining of the lung tissue from control mice, bleomycin-treated mice, and bleomycin-treated mice that received injections of control-MSCs, IPF-MSCs, or anti-miR-199a-5p-IPF-MSCs. Scale bar = 50 μm. f Quantitative analysis of cell survival 14 days post transplantation in bleomycin-treated mice that received control-MSCs, IPF-MSCs, or anti-miR-199a-5p-IPF-MSCs. g PCR shows that the expression of Alu-sx was significantly increased in the anti-miR-199a-5p-IPF-MSC group compared with the IPF-MSC group. Data represent the mean ± SEM from groups of six mice. *p < 0.05; ***p < 0.001